Incyte Corp. share price logo

Incyte Corp.

NASDAQ: INCY

Large Cap

$98.22

-0.77

(-0.78%)

as on

Incyte Corp. Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $96.09
    $99.62
    downward going graph

    2.17%

    Downside

    1.43%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $66.74
    $112.29
    downward going graph

    32.05%

    Downside

    14.32%

    Upside

    downward going graph

Incyte Corp. share price movements today

Previous Close
$98.99
Open
$99.58
Volume
1.3M
Day's Low - High
$96.09 - $99.62
52 Week Low - High
$66.74 - $112.29

Incyte Corp. Historical Returns

1 Month Return
+ 2.74 %
3 Month Return
+ 5.67 %
1 Year Return
+ 43.87 %
3 Year Return
+ 55.34 %
5 Year Return
+ 16.98 %

Incyte Corp. Stock Fundamentals & Key Indicators

Check Incyte Corp. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$19.8B

EPS (TTM)

7.6966

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.84%

PE Ratio (TTM)

13.98

Industry PE ratio

-4.0832

PEG Ratio

0.3585

EBITDA

1.5B

Revenue (TTM)

5.4B

Profit Margin

26.71%

Return On Equity TTM

30.82%

Incyte Corp. Stock Valuation

Track how Incyte Corp. P/E has moved over time to understand its valuation trends.

Incyte Corp. in the last 5 years

  • Overview

  • Trends

Lowest (12.11x)

June 30, 2025

Industry (-4.08x)

June 19, 2026

Today (13.98x)

June 19, 2026

Highest (67.12x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 13.98x

Incyte Corp. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Incyte Corp. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$19.8B16.98%13.9826.71%NA
BUY$37.7B57.21%71.2112.55%NA
BUY$116.5B140.42%27.2235.51%NA
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Incyte Corp. Stock including INR - Dollar returns

The Incyte Corp. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Incyte Corp. investment value today

Current value as on today

₹1,56,715

Returns

₹56,715

(+56.71%)

Returns from Incyte Corp. Stock

₹43,870 (+43.87%)

Dollar Impact

₹12,845 (+12.84%)

Analyst Recommendation on Incyte Corp. Stock

Based on 29 analysts

BUY

55.17%

Buy

44.83%

Hold

0.00%

Sell

Based on 29 analysts, 55.17% of analysts recommend a 'BUY' rating for Incyte Corp.. Average target price of $109.09

Incyte Corp. Share Price Target

Get share price movements and forecasts by analysts on Incyte Corp..

What analysts predicted

9.96%UPSIDE

Target Price

$109.09

Current Price

$98.22

Analyzed by

29 Analysts

Target

$109.09

Incyte Corp. target price $109.09, a slight upside of 9.96% compared to current price of $98.22. According to 29 analysts rating.

Indian Investors' Interest in Incyte Corp. Stock

Search interest for Incyte Corp. Stock has increased by 24% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:24% versus previous 30 day period

Incyte Corp. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
1,013
880
1,043
1,137
1,178
1,052
1,215
1,365
1,506
1,272
Gross Profit
943
819
967
1,051
1,090
979
1,136
1,266
1,385
1,168
Operating Income
187
91
-478
146
297
216
310
431
383
324
EBITDA
293
258
-367
179
336
257
581
506
414
367
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
21
21
22
22
22
22
22
24
23
23
Income Before Tax
270
236
-389
156
313
234
558
482
389
343
Income Tax Expense
69
66
54
50
112
75
153
58
90
40
Net Income
201
169
-444
106
201
158
404
424
299
303
Net Profit Margin
19.84%
19.25%
-42.60%
9.36%
17.07%
15.03%
33.32%
31.05%
19.86%
23.83%

Incyte Corp. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,105
1,536
1,881
2,158
2,666
2,986
3,394
3,695
4,241
5,141
Gross Profit
1,047
1,456
1,787
2,044
2,535
2,835
3,187
3,440
3,929
4,769
Operating Income
144
-243
129
402
-263
585
591
655
101
1,342
EBITDA
204
-253
171
543
-178
630
599
919
408
1,760
Interest Expense
38
6
1
1
2
1
2
2
2
2
Depreciation
-
52
54
54
51
57
67
79
89
93
Income Before Tax
107
-312
115
486
-232
570
529
834
316
1,664
Income Tax Expense
3
0
5
39
63
-378
188
236
284
377
Net Income
104
-313
109
446
-295
948
340
597
32
1,286
Net Profit Margin
9.43%
-20.38%
5.82%
20.70%
-11.09%
31.76%
10.04%
16.17%
0.77%
25.03%

Incyte Corp. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
169
-444
106
201
158
404
424
299
303
Operating Cash Flow
218
-575
310
381
266
44
559
543
369
Investing Cash Flow
-73
213
38
-21
1
-18
-47
-37
-88
Financing Cash Flow
-12
-1,997
-32
20
-12
-11
-12
137
84
Change in Cash
132
-2,358
316
383
253
13
500
642
363

Incyte Corp. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-313
109
446
-295
948
340
597
32
1,286
Operating Cash Flow
-92
336
710
-124
749
969
496
335
1,413
Investing Cash Flow
-349
-86
-87
-269
-207
-78
-207
157
-102
Financing Cash Flow
690
14
45
71
6
0
-20
-2,021
101
Change in Cash
247
264
668
-318
544
893
262
-1,525
1,410

Mutual Funds that own Incyte Corp. Stock

Check out the Mutual Funds with significant holdings in Incyte Corp..

Funds
Holdings
Shares Held
Motilal Oswal S&P 500 Index Fund Direct Growth
Motilal Oswal S&P 500 Index Fund Direct Growth
0.02464%
1228

Global Institutional Holdings in Incyte Corp.

Funds
Holdings
Dimensional Fund Advisors, Inc.
0.99%
UBS Asset Mgmt Americas Inc
0.76%
Baker Bros Advisors LP
15.39%
Vanguard Group Inc
9.97%
Dodge & Cox
6.13%

Incyte Corp. News & Key Events

  • img

    Today's Timeline - 10 February

    Tue, 08:00 PM

    -

    Incyte reports Q4 revenue of $1.51 billion, exceeding estimates, but EPS of $1.80 misses consensus by 7.06%.

Insights on Incyte Corp.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, INCY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 299.27M → 303.33M (in $), with an average increase of 1.3% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, INCY has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, INCY stock has moved down by -9.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.50B → 1.27B (in $), with an average decrease of 15.5% per quarter

About Incyte Corp.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
OrganisationIncyte Corp.
Headquarters1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
IndustryBiotechnology
CEOMr. William J. Meury
E-voting on sharesClick here to vote

Key Management of Incyte Corp.

Name

Title

Mr. Thomas Tray

Principal Financial Officer, VP of Finance & Chief Accounting Officer

Mr. Mohamed Khairie Issa

Executive Vice President & Head of U.S. Commercial

Mr. Suketu P. Upadhyay

Executive VP & CFO

Ms. Pamela M. Murphy

Vice President of Investor Relations & Corporate Communications

Mr. William J. Meury

CEO & Director

Dr. Steven H. Stein M.D.

Executive VP, Head of Late-stage Development & Chief Medical Officer

Mr. Michael James Morrissey

Executive VP & Head of Global Technical Operations

Ms. Alexis Smith

Vice President & Head of Investor Relations

Mr. Richard A. Hoffman J.D., M.B.A.

Executive VP & General Counsel

Dr. Pablo J. Cagnoni M.D., Ph.D.

President and Global Head of R&D

FAQs

What is Incyte Corp. share price today?

Incyte Corp. share price today is $98.22 as on at the close of the market. Incyte Corp. share today touched a day high of $99.62 and a low of $96.09.

What is the 52 week high and 52 week low for Incyte Corp. share?

Incyte Corp. share touched a 52 week high of $112.29 on and a 52 week low of $66.74 on . Incyte Corp. stock price today i.e. is closed at $98.22,which is 12.53% down from its 52 week high and 47.17% up from its 52 week low.

What is Incyte Corp.'s market capitalisation today?

Incyte Corp. market capitalisation is $0.02T as on .

How to invest in Incyte Corp. Stock (INCY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Incyte Corp. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Incyte Corp. Shares that will get you 0.0153 shares as per Incyte Corp. share price of $98.22 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Incyte Corp. Stock (INCY) from India?

Indian investors can start investing in Incyte Corp. (INCY) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Incyte Corp. stock (as per the Rupee-Dollar exchange rate as on ). Based on Incyte Corp. share’s latest price of $98.22 as on June 19, 2026 at 8:46 am IST, you will get 0.1018 shares of Incyte Corp.. Learn more about fractional shares .

What are the returns that Incyte Corp. has given to Indian investors in the last 5 years?

Incyte Corp. stock has given 16.98% share price returns and 27.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?